Yes — for the **regulatory/evidence pattern**, not as a drop-in of MethylPipeline’s methylation stack.

Superfluid’s pitch is a blood-based **cf-mRNA** Alzheimer’s diagnostic (early detection, therapy guidance) with sequencing/qPCR → tissue-specific expression → ML deconvolution. That is a different analyte and algorithm family than MethylPipeline’s methylation DMP / gene FeatureCuts path.

What **does** transfer is the SaMD ladder you built here:

| MethylPipeline SaMD idea | Fit for a Superfluid-like product |
|--------------------------|-----------------------------------|
| `samd_research` → `samd_holdout_enrichment` → `samd_pivotal` | Same claim discipline for any locked ML diagnostic |
| Patient-disjoint `locked_test` / `pivotal_validation` | Essential for Alzheimer’s (same patient over time, longitudinal draws) |
| Lock hyperparameters before enrichment/pivotal | Same — no retuning on holdouts |
| Code-blocked clinical claims until pivotal stage | Same intended-use / performance-claim gate |
| Evidence packages + submission scaffold | Same FDA-style narrative structure |

What **does not** transfer without rebuilding:

- Methylation-specific profiles (`dual_fc`, DMP caps, FeatureCuts)
- Study scaffolds that assume buffy/plasma methylation cohorts
- DomainPrograms that run your MC stability → freeze → model topology on methylation artifacts

For Superfluid you’d keep the **lifecycle and claim controls**, and swap the science layer: cf-mRNA feature pipeline, their ML/deconvolution model, and Alzheimer’s-specific intended use (rule-out/rule-in, staging, treatment selection — each is a different claim boundary).

**Bottom line:** the SaMD *approach* (partitioned cohorts, locked HPs, staged claim gates, evidence packaging) is disease- and analyte-agnostic and fits a Superfluid-style product well. MethylPipeline *as implemented* is the methylation realization of that pattern — you’d reuse the pattern, not the methylation tool chain.
